Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells

Targeted therapies have profoundly changed the clinical prospect in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. In particular, the anti-HER2 monoclonal antibody trastuzumab represents the gold standard for the treatment of HER2+ breast cancer patients. Its contribution in...

Descripción completa

Detalles Bibliográficos
Autores principales: Truffi, Marta, Colombo, Miriam, Sorrentino, Luca, Pandolfi, Laura, Mazzucchelli, Serena, Pappalardo, Francesco, Pacini, Chiara, Allevi, Raffaele, Bonizzi, Arianna, Corsi, Fabio, Prosperi, Davide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920071/
https://www.ncbi.nlm.nih.gov/pubmed/29700387
http://dx.doi.org/10.1038/s41598-018-24968-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920071/
https://www.ncbi.nlm.nih.gov/pubmed/29700387
http://dx.doi.org/10.1038/s41598-018-24968-x

Ejemplares similares